VPHIF (Valeo Pharma) LT-Debt-to-Total-Asset: 0.76 (As of Jul. 2024)


VPHIF Valeo Pharma Inc VPHIF
12 GF Score
Price $0.00
View Full Analysis

What is Valeo Pharma LT-Debt-to-Total-Asset?

Valeo Pharma VPHIF -99.00% 12 LT-Debt-to-Total-Asset is 0.76 as of Jul. 2024. GuruFocus rates VPHIF with a GF Score™ of 12/100.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Valeo Pharma's long-term debt to total assests ratio for the quarter that ended in Jul. 2024 was 0.76.

Valeo Pharma's long-term debt to total assets ratio declined from Jul. 2023 (1.38) to Jul. 2024 (0.76). It may suggest that Valeo Pharma is progressively becoming less dependent on debt to grow their business.

Valeo Pharma  (OTCPK:VPHIF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Valeo Pharma LT-Debt-to-Total-Asset Related Terms

Valeo Pharma LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Valeo Pharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Valeo Pharma LT-Debt-to-Total-Asset Chart

Valeo Pharma Annual Data
Trend Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.17 0.29 0.13 1.04 1.47

Valeo Pharma Quarterly Data
Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.38 1.47 0.87 1.10 0.76
VPHIF
12GF Score
Valeo Pharma Inc VPHIF
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Valeo Pharma LT-Debt-to-Total-Asset Calculation

Valeo Pharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Oct. 2023 is calculated as

LT Debt to Total Assets (A: Oct. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Oct. 2023 )/Total Assets (A: Oct. 2023 )
=44.121/30.052
=1.47

Valeo Pharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jul. 2024 is calculated as

LT Debt to Total Assets (Q: Jul. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Jul. 2024 )/Total Assets (Q: Jul. 2024 )
=17.818/23.476
=0.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.76 mean?
Valeo Pharma (VPHIF) has a LT-Debt-to-Total-Asset of 0.76 as of Jul. 2024. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Valeo Pharma and its competitors.
Is Valeo Pharma's LT-Debt-to-Total-Asset too high?
Valeo Pharma's current LT-Debt-to-Total-Asset is 0.76. Overall, Valeo Pharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Valeo Pharma's LT-Debt-to-Total-Asset compare to ZTS?
Valeo Pharma's LT-Debt-to-Total-Asset of 0.76 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Valeo Pharma and its competitors. Valeo Pharma's current LT-Debt-to-Total-Asset is 0.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valeo Pharma stock overvalued right now?
Valeo Pharma (VPHIF) has a current LT-Debt-to-Total-Asset of 0.76. The current LT-Debt-to-Total-Asset is 0.76. Valeo Pharma's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Valeo Pharma (VPHIF), the current LT-Debt-to-Total-Asset is 0.76 as of Jul. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Valeo Pharma Business Description

Address 16667, Hymus Boulevard, Kirkland, QC, CAN, H9H 4R9
Valeo Pharma Inc is a Canadian specialty pharmaceutical company focused on acquiring either through acquisitions, in-licensing, or similar arrangements. The company operates in two divisions: Branded prescription products and hospital specialty products. Its product portfolio includes medicines for Respiratory/Allergy, Ophthalmology, Neurology, and Oncology.
12GF Score

Get the complete analysis for VPHIF

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price